Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Apogee Therapeutics, Inc.

apogeetherapeutics.com
Filed: Mar 24, 2026Waltham, MassachusettsCIK: 0001974640research
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Apogee Therapeutics successfully completed a $350 million public offering of 5.75 million shares at $70 per share, with full exercise of the underwriters' option, demonstrating strong investor confidence and providing substantial capital for R&D initiatives.

Key Takeaways

Apogee raised $350 million through a public offering of 5 million shares at $70 per share, plus 750,000 additional shares from full exercise of underwriters' option

The offering was underwritten by Jefferies LLC, TD Securities (USA) LLC, Stifel Nicolaus & Company, and Guggenheim Securities

2 more takeaways

Related Filings (1)

1 more filing from Apogee Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 24, 2026
Item1.01
CategoryMaterial Agreement
CIK0001974640
Accession #0001974640
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings